Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ACADEMIA
ACADEMIA
- Patients Need to Be Warned of Risk of Relapse if They Discontinue Antidepressants: Prof. Iwata
October 6, 2011
- Med. Institutions Prefer GE Anticancer Drugs from Companies with Better Support Systems: Ms Matsui of NCC Hospital East
October 3, 2011
- Decision to Prescribe Prazaxa Should Be Left to Specialists for Now: JCS Press Seminar
September 30, 2011
- 95% of Patients Favor Comprehensive Agreements to Use Tissue for Research: NCC
September 26, 2011
- JASSO to Announce New Diagnostic Guidelines for Obesity
September 26, 2011
- Insurers Favor Incentives to Pharmacies to Promote Use of Generics: Seminar
September 26, 2011
- Regulatory Science Society Holds 1st Scientific Convention
September 19, 2011
- NCGM Hospital Removes Actos from List of Recommended Drugs in Diabetes Manual
September 14, 2011
- Clinical Positioning Needs to Be Clarified for Nexavar, Sutent: Prof. Naito of Kyushu Univ.
September 12, 2011
- Intensive Therapy with Rosuvastatin Effective at Inhibiting Progression of IMT: JART Study
September 12, 2011
- Apixaban Superior to Warfarin, Risk of Major Bleeding Down 30%: ESC
September 12, 2011
- 42 Nat’l Univ. Hospitals Share Drug Price Information to Reduce Purchase Costs
September 12, 2011
- NCC Aims to Become World’s Leading Early Clinical Development Center
September 12, 2011
- ”Seller’s Market” for Pharmacists Expected to Continue Over Next Few Years
September 7, 2011
- JCS Recommends Dabigatran in Patients with CHADS2 Score of 1
September 5, 2011
- Osaka Univ. Hospital to Lead Innovation to Discover Globally Competitive Drugs
September 5, 2011
- Univ. of Tokyo Hospital to Initiate PI Trial of Radical AD Treatments
September 5, 2011
- Keio Univ. to Begin PI Trials of New Drugs for Refractory Immunological Diseases in FY2012
September 5, 2011
- Generic Drugs Accounted for 23.1% of Drug Sales Volume in April-June: JGA
September 2, 2011
- National Cancer Center to Set Up Phase I Center by End of FY2011
September 1, 2011
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…